Diphenhydramine/trimethobenzamide

Drug Profile

Diphenhydramine/trimethobenzamide

Alternative Names: Trimethobenzamide/diphenhydramine

Latest Information Update: 27 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Multi-Corp International
  • Developer Compass Point Research; NDA Partners
  • Class Antiallergics; Antiemetics; Antimigraines; Antipruritics; Sedating antihistamines
  • Mechanism of Action Histamine H1 receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Migraine

Most Recent Events

  • 21 Jan 2016 MultiCorp International receives detailed response letter from the FDA for development of diphenhydramine/trimethobenzamide in Migraine
  • 08 Apr 2015 MultiCorp International collaborates with Compass Point and NDA Partners to develop diphenhydramine/trimethobenzamide for the treatment of migraine
  • 08 Apr 2015 Early research in Migraine in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top